Evidence map›Paper›PMID 21523391›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2011

Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.

Luigi Aloj, Michela Aurilio, Valentina Rinaldi, Laura D'ambrosio, Diego Tesauro, Petra Kolenc Peitl, Theodosia Maina, Rosalba Mansi, Elisabeth von Guggenberg, Lieke Joosten and 9 more

Open access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Radiopharmaceutical formulation and preliminary clinical dosimetry of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  3. Effect ofPharmaceutics · 2023
    Article
  4. Review
  5. Automated Synthesis ofMolecules (Basel, Switzerland) · 2022
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Automated preparation of clinical grade [EJNMMI radiopharmacy and chemistry · 2019
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Molecular pharmaceutics · 2017
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 8 countries.

Luigi AlojAF Medicina Nucleare, Istituto Nazionale Tumori, Fondazione G. Pascale, Via M. Semmola, 80131 Naples, Italy. l.aloj@istitutotumori.na.it
Michela Aurilio
Valentina Rinaldi
Laura D'ambrosio
Diego Tesauro
Petra Kolenc Peitl
Theodosia Maina
Rosalba Mansi
Elisabeth von Guggenberg
Lieke Joosten
Jane K Sosabowski
Wouter A P Breeman
Erik De Blois
Stuart Koelewijn
Marleen Melis
Beatrice Waser
Karin Beetschen
Jean Claude Reubi
Marion de Jong
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITErasmus University Rotterdam · NLUniversity of Bern · CHErasmus MC · NLCentro Interuniversitario di Ricerca sui Peptidi Bioattivi · ITInnsbruck Medical University · ATLjubljana University Medical Centre · SINational Centre of Scientific Research "Demokritos" · GRQueen Mary University of London · GBRadboud University Nijmegen · NLUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSpecific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COST Action BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the present study, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project.

methodsDetermination of IC(50) values was performed using autoradiography, with DOTA-peptides displacing (125)I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using (111)In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (K(d)) and apparent number of binding sites (B(max)) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C.

resultsAll peptides showed high receptor affinity with IC(50) values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with K(d) values in the 10(-9)-10(-8) M range. B(max) values estimated in A431-CCK2R cells ranged from 0.6 to 2.2 × 10(6) per cell. All peptides showed high levels of internalization when incubated at 37°C.

conclusionAll DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.

Indexed as

Cooperative BehaviorAmino Acid SequenceAnimalsCell Line, TumorHeterocyclic Compounds, 1-RingHumansIndium RadioisotopesInhibitory Concentration 50Molecular Sequence DataPeptidesProtein BindingProtein TransportRatsReceptor, Cholecystokinin B1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidHeterocyclic Compounds, 1-RingIndium RadioisotopesPeptidesReceptor, Cholecystokinin B

Identifiers

PMID21523391
OpenAlexW2087620192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.